Hikma Pharmaceuticals PLC · LSE:HIK

Hikma Pharmaceuticals — 30th Annual JP Morgan Healthcare Conference 2012

43 slides from Hikma Pharmaceuticals's conference presentation, January 2012

  1. Slide 1: 30th Annual JP Morgan Healthcare Conference

    HIKMA PHARMACEUTICALS PLC 30th Annual JP Morgan Healthcare Conference January 2012

  2. Slide 2: Disclaimer

    ■ This document, which has been issued by Hikma Pharmaceuticals PLC (the “Company”), comprises the written materials/slides for a presentation. This document and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or publis

  3. Slide 3: Group at a glance

    Group at a glance We develop, manufacture and market generic and in-licensed pharmaceutical products within 3 core businesses 2010 Proportion of 2010 Products Key markets Top products Revenue Group revenue Branded ƒ 217 branded MENA: Jordan, Actos ® $394.2 m products Algeria Saudi Algeria, Amoclan A

  4. Slide 4: Our network of high quality manufacturing facilities

    Our network of high quality manufacturing facilities ■ 20 manufacturing facilities in 10 countries -6 FDA approved ■ Cost-effective R&D and manufacturing Ribosepharm GmbH, Germany Thymoorgan GmbH, Germany Hikma Farmaceutica, Portugal Ibn Al Baytar , Medicef, Tunisia Hikma Italia West-ward, USA Hikma

  5. Slide 5: Our revenues by segment and by region

    Our revenues by segment and by region H1 2011 revenue by segment H1 2011 revenue by region 58.2% 50.6% 19.3% 11.4% 0.7% 29.4% 30.4% Branded Generics Injectables Other MENA EU & ROW US Page 4

  6. Slide 6: Branded

    Branded

  7. Slide 7: Strong market growth in 2011 despite the Arab Spring

    Strong market growth in 2011 despite the Arab Spring MENA pharmaceutical market growth 30% 26% 25% 20% 17% 17% 17% 15% 15% 14% 13% 13% 13% 13% 12% 11% 10% 10% 10% 10% 10% 7% 5% 5% 4% 2% 0% Egypt KSA Algeria Morocco UAE Lebanon Tunisia Jordan Kuwait MENA Average 2009/2010 Growth 2011 YTD Growth ■ Whi

  8. Slide 8: Our strong performance in H1 2011 despite market disruptions

    Our strong performance in H1 2011 despite market disruptions Hikma’s leading position in the MENA market Unit sales Value Avg Rx $ Growth Market share Rank (M) $M Price % % MENA PRIVATE MARKET 0 1 496 1,496 4 381 4,381 1 93 1.93 11 7 11.7 100 0 100.0 GLAXOSMITHKLINE 1 113 323 1.86 7.8 7.4 SANOFI 2 9

  9. Slide 9: Our 1,700-strong sales and marketing team across the MENA region

    Our 1,700-strong sales and marketing team across the MENA region Syria Lebanon 3 Tunisia 91 52 J d Jordan I Iraq Morocco 287 58 135 Kuwait 7 Algeria 243 Bahrain 6 & Qatar 7 Libya GCC 55 Egypt Saudi Arabia 83 406 238 UAE 49 Oman 10 Sudan 92 Yemen 41 8

  10. Slide 10: Continued development of our franchise in growing therapeutic areas

    Continued development of our franchise in growing therapeutic areas Overall CNS¹ market: Overall CVD1 market: $ 765 million $1.4 billion ■ Hikma CNS sales up 62.4%, compared to ■ Hikma CVD sales up 20.5%, compared to market growth of 10.9% market growth of 11.7% ■ Since 2007, we have launched 7 CNS

  11. Slide 11: Hikma remains the partner of choice for MENA

    Hikma remains the partner of choice for MENA ƒ Currently marketing 50 in-licensed products ƒ Local manufacturing in largest markets reinforces attractiveness to partners - Multiple facilities audited and approved by Takeda ƒ Latest agreement with Vifor Pharma - Ferinject® for iron deficiency ■ Cellt

  12. Slide 12: Expansion into Morocco completes our MENA footprint

    Expansion into Morocco completes our MENA footprint ■ Acquisition of Promopharm S.A., the 9th largest manufacturer of pharmaceuticals in Morocco1 Promopharm revenue – 2010A Alimentary tract & ■ Acquired 63.9% stake for $111.2 million, an 1% metabolism attractive valuation, and launched tender offer

  13. Slide 13: Injectables

    Injectables

  14. Slide 14: Strong organic revenue growth across our global Injectables business

    Strong organic revenue growth across our global Injectables business Injectables revenue by region H1 2010 H1 2011 +14.6% +21.3% 25.5 MSI 36.4 36.1 31.8 29.8 +39.7% 18.1 13.0 US E Europe MENA Page 13

  15. Slide 15: Specialty segments like injectables are driving growth in the US generic market

    Specialty segments like injectables are driving growth in the US generic pharmaceutical market Product segment Dollar Sales Dollar % Change Orals $29.8 B +14.5% Injectables $6.1 B +49.2% Others $2.6 B +23.4% Dermatologicals $1.7 B +41.3% Nasal $1 6 B $1.6 +35 0% +35.0% Source: IMS Health, National S

  16. Slide 16: Significant supply disruptions are impacting shifts in market share in the US

    Significant supply disruptions are impacting shifts in market share in the US Rank Company Eaches Eaches Chg Eaches % Chg Share Share Chg TOTAL INJECTABLES 1 292 333 1,292,333 44 969 44,969 3 6% 3.6% 100 0% 100.0% 0 0% 0.0% 1 HOSPIRA 517,950 1,721 0.3% 40.1% -1.3% 2 HIKMA / WEST-WARD 218,088 27,727

  17. Slide 17: Strengthening our leading position in generic injectables in the US

    Strengthening our leading position in generic injectables in the US Key strategies ■ Maintain M i t i th the highest hi h t quality lit standards t d d andd service i llevels l ■ Drive down costs and improve ability to compete ■ Utilize scale in high volume products to maintain leadership position H

  18. Slide 18: Excellent opportunities for growth in MENA injectables

    Excellent opportunities for growth in MENA injectables ■ Strong performance in private market Marketed Injectables products by country* - Private market sales +15% in H1 2011 - Strongest performance in Saudi Arabia, Sudan, Iraq and Algeria 12 Syria - 20 product approvals across all Tunisia Lebanon 8

  19. Slide 19: Continuously building our MENA oncology platform

    Continuously building our MENA oncology platform MENA oncology market, by value *** Hikma marketed oncology products in MENA* ■ Zoledronic Acid ■ Epirubicin (Zometa) (Pharmorubicine) Glivec Others & generics ■ Letrozole (Femara) ■ Gemcitabine (Gemzar) ■ Imatinib I ti ib (Glivec) (Gli ) ■ Vinorelbine

  20. Slide 20: Contract manufacturing in US and Europe offers new growth opportunities

    Contract manufacturing in US and Europe offers new growth opportunities Generic value chain Case study: Partnering higher up the value chain API Sourcing ■ Manufacture of iron gluconate for US generic company Formula/Product Development ■ Collaborated on formulation - enhancing R&D capabilities - bu

  21. Slide 21: Generics

    AIKMA QUALITY

  22. Slide 22: Gaining market share through focus on quality and service

    Gaining market share through focus on quality and service MAT 6/09 MAT 6/10 MAT 6/11 1H 2011 Orals ((000s)) ((000s)) ((000s)) ((000s)) US generic oral market Total prescriptions written 2,341,692 2,506,333 2,675,385 1,354,986 Market growth +7.0% +6.7% +4.0% Hikma (West (West-Ward) Ward) Total prescr

  23. Slide 23: Leveraging our MENA capacity for the US market

    Leveraging our MENA capacity for the US market Percentage of Generics sales produced in MENA* +25.1% +24.8% +21.2% +20.9% +9 4% +9.4% +7.2% 2007 2008 2009 2010 H1 2010 H1 2011 Oral generic products produced at our FDA approved facilities in Jordan and Saudi Arabia and sold in the US Note: Sales figu

  24. Slide 24: Building on our capabilities in the US market

    Building on our capabilities in the US market Key strategies ■ Maintain M i t i th the highest hi h t quality lit standards t d d andd service i llevels l ■ Drive down costs and improve ability to compete  Site transfer products to Jordan to improve cost competitiveness titi Hikma aims to strengthe

  25. Slide 25: API sourcing and R&D

    API sourcing and R&D

  26. Slide 26: Strategic investments enhance API sourcing and R&D capabilities

    Strategic investments enhance API sourcing and R&D capabilities Unimark Haosun ■ One of India’s leading manufacturers of API ■ Chinese pharmaceutical company that and API intermediates. manufactures and supplies the domestic Chinese and international markets ■ Three Th API facilities, f iliti ttwo o

  27. Slide 27: Our strong track record of revenue growth

    Our strong track record of revenue growth Acquired Baxter’s Multi Source Injectables (US) in May 2011 Acquired minority stake in India’s Unimark and China’s Haosun Group revenues ($ million) Acquired 63.9% of Promopharm in Morocco Inauguration of Dar Al Arabia in Algeria Acquired Ibn Al Acquired Rib

  28. Slide 28: Appendix

    Appendix

  29. Slide 29: Resilient H1 performance

    Resilient es e H1 pe performance o a ce All figures in $ million H1 2011 H1 2010 Change Net sales 394.8 357.7 +10.4% Gross profit 172.6 178.5 -3.3% Gross margin 43.7% 49.9% -6.2 Operating profit 49.0 74.3 -34.0% Operating margin 12.4% 20.8% -8.4 j Adjusted 1 operating p g profit p 60.3 73.2 -17.5% A

  30. Slide 30: Currency movements impact reported results

    Currency movements impact reported results Euro/USD Jan 2010 - June 2011 USD/SDG Jan 2010 - June 2011 USD/JPY Jan 2010 - June 2011 H1 2011 Avg 2011 Spot H1 2010 H1 2011 vs 2011 vs Avg Avg H1 2010 Avg Spot(3) H1 2010 Avg Yen (1) 91.47 81.94 11.6% 76.62 19.4% SDG (2) 2.39 3.07 -28.4% 2.90 -21.5% Euro

  31. Slide 31: Branded: Resilient performance despite MENA disruption

    Branded Resilient performance despite MENA disruption Revenues ($ million) 240 ■ Sales growth of 3% despite impact of Arab Spring + 4.9% 203.3 200 ■ Double-digit growth across many MENA markets 199.6 193.8 + 3.0% 160 ■ Stronger growth expected in the second half of 2011 120 80 40 0 H1 2010 H1 2011 R

  32. Slide 32: Branded: Quick response to market events limits impact on profitability

    Branded Quick response to market events limits impact on profitability Gross profit ($ million) Operating profit ($ million) 120 60 116.1 - 2.9% -16.8% 54.3 Revaluation 100 gain impact 102.2 99.2 47.1 of $7.2 - 4.1% 45.2 million 80 40 60 40 20 20 0 0 H1 2010 H1 2011 H1 2010 H1 2011 Gross margin Oper

  33. Slide 33: Injectables: Excellent performance across global Injectables business

    Injectables Excellent ce e peperformance o a ce ac across oss g global oba Injectables jec ab es bus business ess Revenues ($ million) ■ Excellent organic sales growth of 21.6% - driven 120 by increased revenue across US, MENA and Europe H1 2011 S l Sales G Growth th + 55.9% 116.1 US $18.1m 39.7% 90

  34. Slide 34: Injectables: MSI expected to break even for second half of 2011

    Injectables MSI S eexpected pec ed to o break b ea even e e for o the e second seco d half a o of 2011 0 Summary P&L H1 2011 ■ MSI contributed $25.5 $ million $ million Group MSI Inventory & Exceptional Group of incremental sales ex MSI amortisation items Consolidated adjustments Revenue 369.2 25.5

  35. Slide 35: Injectables: Increasing scale drives continued margin expansion

    Injectables Increasing c eas g scale sca e d drives es co continued t ued margin ag e expansion pa s o Gross profit ($ million) Operating profit ($ million) 50 20 + 27.0 % 18 40 43.6 16 37.9 14 + 41.0% 14.9 + 10.6% 10 6% 30 34.3 12 13.3 Group 10 + 26.5% Group incl. MSI 10.6 ex MSI 20 8 Group Group e

  36. Slide 36: Generics: Double-digit revenue growth, excluding colchicine

    Generics Double-digit g revenue g growth,, excluding g colchicine Revenues ($ million) ■ Reported sales declined by 12 12.4% 4% 100 - 12.4 % ■ Excluding colchicine sales in H1 2010, Generics 87.2 80 achieved double-digit growth in H1 2011 76.4 60 ■ Volume growth more than offset the slight increases

  37. Slide 37: Generics: Return to sustainable margins

    Generics Return to sustainable margins g Gross profit ($ million) Operating profit ($ million) 45 30 40 41.8 35 - 30.1% 25 26.1 30 - 61.1% 20 29.2 25 15 20 15 10 10.2 10 5 5 0 0 H1 2010 H1 2011 H1 2010 H1 2011 Gross margin Operating margin H1 2010 H1 2011 Change H1 2010 H1 2011 Change 47.9% 38.3% -

  38. Slide 38: Operating expenses: Strengthening the business to support future growth

    Operating expenses Strengthening g g the business to support pp future g growth Operating expenses as a % of Group revenue ■ S&M expenses stables as % of sales - Investment in S&M team in MENA H1 2011 H1 2010 Change - Economies of scale in global „ Sales & Marketing 14.4% 14.7% - 0.3 Injectables „ G

  39. Slide 39: Cash Flow: MSI transaction increases working capital requirement

    Cash Flow MSI transaction increases working capital requirement Operating Cash Flow ($ million) ■ Operating cash flow reduced, funding the working 70 Group capital requirement of the MSI business and ex MSI increased Group inventory levels 65.3 Group 60 incl. MSI ■ Working capital days increased to

  40. Slide 40: MENA investment reflects optimism for growth and commitment to region

    Capital expenditure MENA investment reflects optimism p for g growth and commitment to region g Capital expenditure ($ million) 40 ■ Expansion E i iin MENA manufacturing f t i capabilities 35 33.2 - Algeria, Egypt and Tunisia 30 + 41.2% 41 2% 43 4.3 3.1 ■ Machinery and equipment for new 25 23.4 25.8

  41. Slide 41: Leverage ratios remain comfortable

    Balance sheet Leverage g ratios remain comfortable Net debt position ($ million) 150 ■ Increase in net debt reflects three acquisitions completed in the first half 92.0 100 ■ Leverage ratios remain comfortable 68.0 50 Short-term Long-term H1 2010 H1 2011 borrowing borrowing 0 Net debt 123.6 322.7 Ca

  42. Slide 42: Cash flow

    Cash flow All figures in $ million H1 2011 H1 2010 Profit before tax and minority interest 39 9 39.9 67 5 67.5 Adjustments for non-cash items 38.8 23.1 Change in working capital (54.6) (7.3) Income tax paid (4.8) (18.0) Net cash generated from operating activities 19.2 65.3 Investment in property, p

  43. Slide 43: Balance sheet

    Balance sheet All figures in $ million H1 2011 H1 2010 Change $ Change % Cash 92.0 68.0 24.0 35.3% Trade and other receivables 273.2 238.9 34.3 14.4% Other current assets 2.9 1.0 1.9 181.3% Inventories 269.5 171.4 98.0 57.2% Total current assets 637.7 479.5 158.2 33.0% IIntangible t ibl assets t 294

Hikma Pharmaceuticals — 30th Annual JP Morgan Healthcare Conference 2012 on 6ix